Expedeon

Expedeon

Reagents and kits for protein-based research.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

€120m

Acquisition
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR20172018
Revenues00000000
% growth-(86 %)
EBITDA00000000
% EBITDA margin20 %(11 %)
Profit00000000
% profit margin100 %86 %
EV00000000
EV / revenue00.0x00.0x
EV / EBITDA00.0x00.0x
R&D budget00000000

Source: Company filings or news article

Notes (0)
More about Expedeon
Made with AI
Edit

Expedeon operated as a specialized life sciences entity, providing reagents and kits to the protein-based research market. The company was originally founded in 2003 in the United Kingdom and later evolved through a series of corporate changes, including operating as the German public company Sygnis AG, which was renamed Expedeon AG in 2018. The firm's business model was centered on a "Grow, Buy, and Build" strategy, which involved driving organic growth through internal R&D, acquiring complementary companies, and integrating them to expand its technology portfolio and market reach. This strategy successfully expanded its customer base from a primarily academic focus to include industrial clients in the diagnostics and pharmaceutical sectors.

The company's product portfolio was extensive, offering solutions for protein electrophoresis, proteomics, protein purification, Western Blotting, and sample preparation. Key product lines included the InstantBlue protein stain, Lightning-Link® antibody and protein labeling kits, and CaptSure™ immunoassay technology. These products were designed to streamline complex laboratory processes, for instance, the Lightning-Link® kits enabled antibody conjugation in under 30 seconds. The business served life science researchers in both academic institutions and industrial settings, enabling the development of new diagnostics and therapeutics.

A significant milestone occurred in January 2020 when Expedeon AG's proteomics and immunology business was acquired by Abcam plc for a sum of €120 million. This transaction included flagship brands like Lightning-Link® and CaptSure™. Following the divestment, Expedeon AG rebranded to 4basebio AG, shifting its strategic focus towards DNA manufacturing for the gene therapy and gene vaccine markets. The remaining genomics business was subsequently spun off into a new entity, 4basebio SE, listed on the London Stock Exchange, while 4basebio AG continued as an investment-focused company.

Keywords: proteomics, life science reagents, antibody conjugation, protein labeling, immunoassay technology, Western Blotting, protein purification, electrophoresis, genomics, DNA manufacturing, diagnostics development, drug discovery, Lightning-Link, CaptSure, InstantBlue, Abcam, 4basebio, life sciences research, protein analysis, biomarker research

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Expedeon

Edit
Protein Discovery
ACQUISITION by Expedeon Nov 2011